ArticlePharmacogenomics2016
CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.
Article in Pharmacogenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.British journal of clinical pharmacology · 2019Trial
- Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers.Molecular psychiatry · 2025Article
- PharmVar GeneFocus: CYP2A6.Clinical pharmacology and therapeutics · 2024Review
- Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data.Journal of human genetics · 2023Article
- Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke.Clinical and translational science · 2021Article
- Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Article
- Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.Addiction biology · 2020Article
- Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers.Drug and alcohol dependence · 2019Article
- Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence.Clinical pharmacology and therapeutics · 2019Article
- Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.Addiction (Abingdon, England) · 2018Article
- Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.Trends in molecular medicine · 2018Review
- Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.Pharmacogenetics and genomics · 2018Article
- Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.Pharmacogenetics and genomics · 2017Article
- Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.Journal of clinical pharmacology · 2017Article
- Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.The Journal of pharmacology and experimental therapeutics · 2017Article
- Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.Pharmacogenetics and genomics · 2016Article
- Biochemistry of nicotine metabolism and its relevance to lung cancer.The Journal of biological chemistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
CYP2A6 genotyping is of clinical importance--CYP2A6 gene variants influence nicotine metabolism and are associated with nicotine dependence, cigarettes per day, smoking cessation and the risk for tobacco-associated cancers. CYP2A6 gene variants also influence the metabolism of therapeutic drugs, such as the anticancer agents, tegafur and letrozole. Over the years, CYP2A6 genotyping methods have evolved to incorporate novel gene variants and to circumvent genotyping errors resulting from the high degree of homology between CYP2A6 and neighboring CYP2A genes. Herein, CYP2A6 genotyping strategies are described for commonly genotyped functionally significant alleles including SNPs, small insertions/deletions and more complex structural variants. The methods presented utilize higher throughput SYBR green real-time PCR technology in addition to standard thermocycling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.